A study demonstrated that reducing the expression of several inhibitory molecules, including TIM-3, in CAR T cells resulted in robust immunity against CCA, exhibiting long-term efficacy both in vitro and in vivo (159). Here, HAVCR2 is linked to cholangiocarcinoma.